Enavogliflozin

SGLT2 inhibitor used for the treatment of type 2 diabetes

Enavogliflozin

Enavogliflozin is a medication used in the management of type 2 diabetes. It belongs to a class of drugs known as SGLT2 inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the blood, thereby lowering blood sugar levels.

Mechanism of Action

Enavogliflozin inhibits the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubules of the kidney. This inhibition reduces the reabsorption of glucose from the renal filtrate, leading to increased glucose excretion in the urine and a reduction in blood glucose levels.

Indications

Enavogliflozin is indicated for the treatment of type 2 diabetes in adults. It is often prescribed when diet and exercise alone do not provide adequate glycemic control. It may be used as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin.

Side Effects

Common side effects of enavogliflozin include:

• Urinary tract infections
• Genital mycotic infections
• Increased urination
• Hypotension

Serious but less common side effects may include:

• Ketoacidosis
• Acute kidney injury
• Hypoglycemia (when used with insulin or sulfonylureas)

Contraindications

Enavogliflozin is contraindicated in patients with:

• Severe renal impairment
• End-stage renal disease
• Hypersensitivity to the drug or its components

Pharmacokinetics

Enavogliflozin is administered orally and has a bioavailability of approximately __%. It is primarily metabolized in the liver and has an elimination half-life of __ hours. The drug is excreted mainly through the urine.

Research and Development

Enavogliflozin is currently undergoing various clinical trials to evaluate its efficacy and safety in different populations and in combination with other antidiabetic medications.

See Also

• Type 2 diabetes
• SGLT2 inhibitors
• Metformin
• Insulin